Search

Search Constraints

You searched for: Author/Creator Giaccone, Giuseppe

Search Results

1. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014)

2. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014)

3. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation. Issue 4 (26th January 2021)

4. An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice. Issue 1 (13th November 2017)

5. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Issue 10 (October 2022)

7. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. (August 2019)

8. Combined Pan‐HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study. Issue 5 (May 2016)